Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc. - Common Shares (NQ:ONCY)

0.9804 +0.0204 (+2.13%)
Streaming Delayed Price Updated: 1:56 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncolytics Biotech Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
Results met efficacy criteria for enrollment expansion and provide support for pelareorep’s mechanism of action San Diego, CA and Calgary, AB – October 23, 2023 – Oncolytics Biotech® Inc. (NASDAQ:... 
Via FinancialNewsMedia
News headline image
Oncolytics Biotech's Earnings: A Preview ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Oncolytics Biotech ↗
 
Via Benzinga
News headline image
Expert Ratings for Oncolytics Biotech ↗
 
Via Benzinga
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing important proof-of-concept San Diego, CA and... 
Via FinancialNewsMedia
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC) EQNX::TICKER_END 
Via FinancialNewsMedia
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END 
Via FinancialNewsMedia
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END 
Via FinancialNewsMedia
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The... 
Via FinancialNewsMedia
News headline image
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON, MA., San Diego, CA., and Calgary, AB. – September 26,... 
Via FinancialNewsMedia
News headline image
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
Via FinancialNewsMedia
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress... 
Via FinancialNewsMedia
Pancreatic Cancer Battle Boosted by $200M VC Firm
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food... 
Via FinancialNewsMedia
News headline image
3 Under-$20 Stocks to Buy for Explosive Returns ↗
Are you looking to invest in stocks with massive potential? Here are three under $20 stocks to buy for explosive returns. 
Via InvestorPlace
News headline image
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
News headline image
Oncolytics Biotech’s® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional... 
Via FinancialNewsMedia
News headline image
Earnings Scheduled For August 14, 2023 ↗
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
News headline image
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END 
Via FinancialNewsMedia
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making... 
Via FinancialNewsMedia
News headline image
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel... 
Via FinancialNewsMedia
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool. 
Via Benzinga
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.